Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Gastrointestinal 1

Conditions

Breast Neoplasms 62Carcinoma, Non-Small-Cell Lung 45Triple Negative Breast Neoplasms 24Ovarian Neoplasms 20Fallopian Tube Neoplasms 17Neoplasm Metastasis 16Lung Neoplasms 16Endometrial Neoplasms 15Squamous Cell Carcinoma of Head and Neck 14Stomach Neoplasms 12Esophageal Neoplasms 10Neoplasms 9Parkinson Disease 4, Autosomal Dominant Lewy Body 8Esophageal Squamous Cell Carcinoma 8Colorectal Neoplasms 7Inflammatory Breast Neoplasms 6Head and Neck Neoplasms 6Carcinoma 6Uterine Cervical Neoplasms 5Carcinoma, Ovarian Epithelial 5Melanoma 4Carcinoma, Transitional Cell 4Carcinoma, Squamous Cell 4Adenocarcinoma Of Esophagus 4Urinary Bladder Neoplasms 3Peritoneal Neoplasms 3Pancreatic Neoplasms 3Oropharyngeal Neoplasms 3Mouth Neoplasms 3Lung Diseases 3

Interventions

durvalumab 7Bevacizumab 6tremelimumab 3Nivolumab 3lenvatinib 2fludarabine 2Cyclophosphamide 2zimberelimab 1toripalimab 1ropidoxuridine 1relatlimab 1pembrolizumab 1fludarabine phosphate 1atezolizumab 1X-Rays 1Technetium Tc 99m Aggregated Albumin 1Standard of Care 1Specimen Handling 1Radiotherapy, Intensity-Modulated 1Radiosurgery 1Radionuclide Imaging 1Platinum 1Photons 1Paclitaxel 1Observation 1Long-Term Potentiation 1Lidocaine 1Immunotherapy 1Immunoglobulin G 1IMC-001 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Liver Neoplasms × Paclitaxel × Clear all
NCT04008797 2026-03-24

A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor

Eisai Inc.

Phase 1/2 Active not recruiting
301 enrolled
GastrointestinalGynecologic

Carcinoma, Hepatocellular, Liver Neoplasms, Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡